Gufic Biosciences Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Gufic Biosciences Ltd filed with BSE on 05 Jun 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Gufic Biosciences reported Q4 FY26 revenue of around INR252 crores, its strongest quarter ever, with EBITDA margin expanding to 17.73% from 13.17% a year earlier and PAT more than doubling year-over-year. Full year FY26 revenue was INR940.50 crores versus INR820 crores in FY25, with EBITDA of INR152.9 crores and PAT of INR63.2 crores. Management attributed the quarterly improvement to the Indore facility reaching EBITDA breakeven at 30% capacity utilization, a working capital reset in the Critical Care cluster, and growth in the women's health and aesthetics platforms.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue: INR252 crores (Q4 FY26)
p. 4
“Revenue in Q4 was around INR252 crores, our strongest quarter ever.”
Avik Das, page 4 of the filed PDF · View the filing
EBITDA: INR44.7 crores (Q4 FY26)
p. 4
“EBITDA came in at almost INR44.7 crores with a margin of 17.7%, up from 13.2% in Q4 of the prior year, and the PAT more than doubled year-over-year in this quarter.”
Avik Das, page 4 of the filed PDF · View the filing
Revenue: INR940-odd crores (FY26)
p. 3
“So when you look at the full year numbers, INR940-odd crores in revenue and a PAT of INR63 crores on the surface, it may look like a flattish year.”
Avik Das, page 3 of the filed PDF · View the filing
EBITDA margin: 17.73% (Q4 FY26)
p. 6
“The EBITDA margin for Q4 of the current financial year is 17.73%.”
Devkinandan Roonghta, page 6 of the filed PDF · View the filing
EBITDA margin: 13.17% (Q4 FY25)
p. 6
“The EBITDA margin in the Q4 of last financial year was 13.17%.”
Devkinandan Roonghta, page 6 of the filed PDF · View the filing
PBT: INR27.6 crores (Q4 FY26)
p. 6
“Profit before tax Q4 of the last year was INR10.8 crores and the Q4 for the current financial year is 27.6 crores.”
Devkinandan Roonghta, page 6 of the filed PDF · View the filing
PAT: INR20.5 crores (Q4 FY26)
p. 6
“Profit after tax Q4 of the last year was INR8 crores. This year, Q4 is INR20.5 crores.”
Devkinandan Roonghta, page 6 of the filed PDF · View the filing
Revenue: INR820 crores (FY25)
p. 6
“The top line for financial year '24-'25 was INR820 crores. The top line for financial year '25-'26 was INR940.50 crores.”
Devkinandan Roonghta, page 6 of the filed PDF · View the filing
EBITDA: INR152.9 crores (FY26)
p. 6
“The EBITDA for the financial year '24-'25 was INR 138.6 crores. The EBITDA for the financial year '25-'26 is INR 152.9 crores.”
Devkinandan Roonghta, page 6 of the filed PDF · View the filing
EBITDA margin: 16.26% (FY26)
p. 6
“The EBITDA margin for the financial year '24-'25 was 16.91%. The EBITDA margin for the financial year '25-'26 is 16.26%.”
Devkinandan Roonghta, page 6 of the filed PDF · View the filing
PAT: INR63.2 crores (FY26)
p. 6
“The profit after tax for the financial year '24-'25 was INR69.9 crores, the financial year '25-'26 is 63.2 crores.”
Devkinandan Roonghta, page 6 of the filed PDF · View the filing
Indore capacity utilization: 30% (Q4 FY26)
p. 4
“We told you at the start of the year that we would reach 30% capacity utilization by year-end. We got there on target.”
Avik Das, page 4 of the filed PDF · View the filing
Botulinum Toxin market share: approximately 23% (FY26)
p. 5
“we are now firmly the number 2 brand in India, sitting at approximately 23% market share in a market where the innovator holds dominant position.”
Avik Das, page 5 of the filed PDF · View the filing
Working capital revenue impact in Critical Care: INR22 crores (FY26)
p. 5
“That transition roughly caused INR22 crores in revenue impact spread across the second, third and the fourth quarter”
Avik Das, page 5 of the filed PDF · View the filing
Total debt: around INR400 crores (current)
p. 10
“Today, our debt is around INR400 crores, total debt, gross debt is around INR400 crores.”
Devkinandan Roonghta, page 10 of the filed PDF · View the filing
Botulinum Toxin contribution to revenue: around 3.5% (FY26)
p. 9
“Totally, it must be contributing to around 3.5% plus or minus to the total revenue.”
Pranav Choksi, page 9 of the filed PDF · View the filing
Export contribution to revenue: 20%, 22% (current)
p. 14
“So export is around 20%, 22%. CMO was around 18%, 19%, and domestic business would be around 48% to 50% and remaining would be APIs and tenders and other businesses.”
Pranav Choksi, page 14 of the filed PDF · View the filing
API outsourcing level: around 65% (current)
p. 12
“Earlier, maybe we were 80%, 85% outsourced. Now we have come to around 65%.”
Pranav Choksi, page 12 of the filed PDF · View the filing
R&D spend: 8% to 10% of top line
p. 18
“we spend 8% to 10% of our top line revenue in our R&D budget every year, which I don't know how many companies of our size do that.”
Pranav Choksi, page 18 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 15% year-over-year
stated as an aspiration by Pranav Choksi
p. 10
“So firstly, as I always have been saying for the past few quarters, we expect a 15% revenue jump year-over-year.”
Pranav Choksi, page 10 of the filed PDF · View the filing
Gross margin — 0.5% to 1% improvement year-over-year
stated as an aspiration by Pranav Choksi
p. 10
“So that's why but I still feel on a minimum level, 0.5% gross margins will be possible.”
Pranav Choksi, page 10 of the filed PDF · View the filing
EBITDA margin — around 18% · FY27
stated as an aspiration by Devkinandan Roonghta
p. 10
“After the scale-up of the Indore, I feel the EBITDA margin for '26, '27 should be in the range of around 18%.”
Devkinandan Roonghta, page 10 of the filed PDF · View the filing
EBITDA margin — above 20% · by 2030
stated as an aspiration by Devkinandan Roonghta
p. 10
“And it can go up to by 2030, it can go above 20%. That is our EBITDA margin.”
Devkinandan Roonghta, page 10 of the filed PDF · View the filing
Total debt — INR400 crores · next 2 to 3 years
stated conditionally by Devkinandan Roonghta
p. 10
“So we feel this INR400 crores will be the top test loan, and it is going to remain at this level only.”
Devkinandan Roonghta, page 10 of the filed PDF · View the filing
Navsari EBITDA margin — 18% to 18.5%
stated as an aspiration by Devkinandan Roonghta
p. 13
“So the Indore margin, sorry, Navsari margin was 20%, and because of increasing the cost every year, we feel that Navsari margin is going to remain at around 18% to 18.5%.”
Devkinandan Roonghta, page 13 of the filed PDF · View the filing
Indore EBITDA margin — 31% to 32%
stated as an aspiration by Devkinandan Roonghta
p. 13
“Therefore, the Indore margin, we expect around 31% to 32%. The overall EBITDA margin will be going to Indore in the range of 20%.”
Devkinandan Roonghta, page 13 of the filed PDF · View the filing
New product launch contribution — INR20 crores to INR25 crores net delta annually
stated as an aspiration by Pranav Choksi
p. 13
“So the net delta would be around INR20 crores, INR25 crores till, of course, some also new blockbuster comes”
Pranav Choksi, page 13 of the filed PDF · View the filing
Critical care growth — 6% to 8%, maximum 9% · this year
stated conditionally by Pranav Choksi
p. 14
“But even if the volumes increased by maybe double digits, the growth which we are putting up this year and budgeting will be around 6% to 8% only or maximum to 9%”
Pranav Choksi, page 14 of the filed PDF · View the filing
Business mix at peak — domestic 40-45%, CMO 15-18%, export around 30%
stated as an aspiration by Pranav Choksi
p. 14
“So I still say that, if you see at peak also, it would be at around 40% to 45% of domestic, CMO will be around 15% to 18% and export will be around 30% plus or minus.”
Pranav Choksi, page 14 of the filed PDF · View the filing
US FDA operations start — 2028 or 2029
stated conditionally by Pranav Choksi
p. 16
“And that's why we are confident of 2029 or 2028 also, U.S. operations to start, provided everything goes well.”
Pranav Choksi, page 16 of the filed PDF · View the filing
API self-reliance — 50% of API done in-house · eventually
stated as an aspiration by Pranav Choksi
p. 12
“Down the line, we hope that 50% of our API can be done in-house eventually.”
Pranav Choksi, page 12 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said margin improvement comes from a mix shift between domestic, international and CMO, new molecule launches, and upgrading to more profitable geographies, expecting 0.5% to 1% gross margin improvement per year.
Answered by Pranav Choksi
Asked by Bhavya Sonawala: Are the improved margins sustainable and what is driving them?
p. 7
“So these will continue to help us to go for the improvement of 0.5% to 1% year-over-year gross margin improvement.”
Pranav Choksi, page 7 of the filed PDF · View the filing
Management said it was too early to quantify, as the company will act as a CDMO/CMO and revenue depends on partners' front-end efforts.
Answered by Pranav Choksi
Asked by Bhavya Sonawala: Can revenue from GLP-1 validation batches be quantified?
p. 7
“It's too premature. If you see both India and international are going to have 2 different road maps.”
Pranav Choksi, page 7 of the filed PDF · View the filing
Management explained it is tied to a long banking relationship with Saraswat Bank, offering a dividend yield higher than the borrowing cost.
Answered by Devkinandan Roonghta
Asked by Nitya Shah: What is the rationale for the investment in the cooperative bank shares?
p. 8
“The bank has come with the proposal to allot only around 24 top customers for this year allotment as a face value of INR10 each.”
Devkinandan Roonghta, page 8 of the filed PDF · View the filing
Management said toxin and aesthetics contribute about 3.5% of revenue currently, with expected market share and market expansion from the new filler partnership.
Answered by Pranav Choksi
Asked by Vishal Mehta: What is the current size of the Botulinum Toxin business and growth outlook?
p. 10
“So we feel that market expansion also will be helpful. At the same time of market share increase also would be there because of this relationship.”
Pranav Choksi, page 10 of the filed PDF · View the filing
Management said dossier and registration costs will rise but expects gross margin improvement over time as more markets shift to a controlled B2C model.
Answered by Pranav Choksi
Asked by Kumar Saurabh: How will the shift from distributor-led to IP-owned international model affect the P&L?
p. 11
“In spite of them, we will see a 0.5% to 1% improvement because more and more investment is being done in terms of getting the dossier processes done.”
Pranav Choksi, page 11 of the filed PDF · View the filing
Management indicated Navsari margins would settle around 18-18.5% due to rising costs while Indore margins should reach 31-32%.
Answered by Devkinandan Roonghta
Asked by Harsh Shah: What is the outlook for Navsari margins versus Indore margins as Indore ramps up?
p. 13
“Whereas in case of Indore, because of the new plant, energy efficient plant and large size of life-leisure product.”
Devkinandan Roonghta, page 13 of the filed PDF · View the filing
Management said cash flow generation from critical care would be around 12-13% of total sales, with domestic collections at 30-45 days and CMO at 90-120 days.
Answered by Devkinandan Roonghta
Asked by Kumar Saurabh: What cash flow conversion is expected from the critical care business after the working capital reset?
p. 14
“The cash flow generation will be around 12% to 13% of the total sales of the critical care division.”
Devkinandan Roonghta, page 14 of the filed PDF · View the filing
Management described a phased, risk-controlled approach, starting as a CMO then progressing to CDMO, without compromising other growth markets.
Answered by Pranav Choksi
Asked by Nitya Shah: What is the vision for becoming a pure-play CDMO partner for US FDA by FY29?
p. 16
“We want to start to be as a CMO, then a CDMO, where our risks are very well defined and controlled in a black-and-white manner”
Pranav Choksi, page 16 of the filed PDF · View the filing
Management declined to comment on the competitor specifically but explained that recent years' higher costs reflect investment in Indore capacity, dossiers and regulatory expansion, which should yield benefits over the next few years.
Answered by Pranav Choksi
Asked by Madhur Rathi: How does Gufic's margin profile compare to competitor Sakar Healthcare and what explains the gap?
p. 18
“So answering your question related to the Gufic, we foresee that whatever investment was supposed to be done in capex is done.”
Pranav Choksi, page 18 of the filed PDF · View the filing
Risks flagged
Currency and geopolitical volatility affecting gross margin gains
p. 10
“But always something like what happened just recently like the Middle East issue, and there are always challenges and the rupee and the dollar equation also changing, sometimes at 1%, 1.1% suddenly goes to 0.5%, 0.6%.”
Pranav Choksi, page 10 of the filed PDF · View the filing
Unsustainable receivables in Critical Care hospital billing
p. 5
“We went into FY26 with outstanding receivables from direct hospital billing that was sitting at almost 140, 150 days plus, and that was simply not sustainable.”
Avik Das, page 5 of the filed PDF · View the filing
Price erosion in critical care despite volume growth
p. 14
“So for the critical care, we foresee because even when the volumes are increasing higher, there's always a price erosion, which happens there.”
Pranav Choksi, page 14 of the filed PDF · View the filing
Complexity and risk of US FDA regulated market entry
p. 16
“Again, U.S. FDA is a very complex market, and the front-end risk are quite I would say, different than what we are used to.”
Pranav Choksi, page 16 of the filed PDF · View the filing
CMO business margin pressure and saturation from GLP-1 dependence
p. 15
“CMO business is something which again, I'm repeating, the GLP-1 is a, I would say, this year, maybe next year phenomena also because you see that saturation coming in down the line as a CMO partner.”
Pranav Choksi, page 15 of the filed PDF · View the filing
Rising costs from manpower and geography expansion increasing other expenses
p. 11
“Of course, initially, there is a little bit of a cost escalation because of registration costs because of, again, dossier costs and also manpower costs because last year also, there was some expansion of manpower done for certain geographies.”
Pranav Choksi, page 11 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.